ATE318908T1 - Synthetische gene für gagpol und deren verwendungen - Google Patents

Synthetische gene für gagpol und deren verwendungen

Info

Publication number
ATE318908T1
ATE318908T1 AT00110623T AT00110623T ATE318908T1 AT E318908 T1 ATE318908 T1 AT E318908T1 AT 00110623 T AT00110623 T AT 00110623T AT 00110623 T AT00110623 T AT 00110623T AT E318908 T1 ATE318908 T1 AT E318908T1
Authority
AT
Austria
Prior art keywords
gagpol
synthetic genes
generation
synthetic gag
gagpol genes
Prior art date
Application number
AT00110623T
Other languages
English (en)
Inventor
Ralf Wagner
Markus Graf
Ludwig Deml
Kurt Bieler
Original Assignee
Geneart Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8168767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE318908(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Geneart Gmbh filed Critical Geneart Gmbh
Application granted granted Critical
Publication of ATE318908T1 publication Critical patent/ATE318908T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00110623T 2000-05-18 2000-05-18 Synthetische gene für gagpol und deren verwendungen ATE318908T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00110623A EP1156112B1 (de) 2000-05-18 2000-05-18 Synthetische Gene für gagpol und deren Verwendungen

Publications (1)

Publication Number Publication Date
ATE318908T1 true ATE318908T1 (de) 2006-03-15

Family

ID=8168767

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00110623T ATE318908T1 (de) 2000-05-18 2000-05-18 Synthetische gene für gagpol und deren verwendungen
AT01960229T ATE333503T1 (de) 2000-05-18 2001-05-18 Synthetische gene für gagpol und deren verwendungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01960229T ATE333503T1 (de) 2000-05-18 2001-05-18 Synthetische gene für gagpol und deren verwendungen

Country Status (10)

Country Link
US (3) US7378515B2 (de)
EP (2) EP1156112B1 (de)
CN (1) CN1429270A (de)
AT (2) ATE318908T1 (de)
AU (1) AU2001281781A1 (de)
BR (1) BR0110706A (de)
CA (1) CA2408433A1 (de)
DE (2) DE60026199T2 (de)
HK (2) HK1042319B (de)
WO (1) WO2001088141A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001294562B2 (en) * 2000-09-15 2007-05-24 Merck & Co., Inc. Enhanced First Generation Adenovirus Vaccines Expressing Codon Optimized HIV1-Gag, Pol, Nef and Modifications
EP1201750A1 (de) 2000-10-26 2002-05-02 Genopoietic Synthetische Viren und ihre Verwendungen
JP4601956B2 (ja) * 2001-09-20 2010-12-22 グラクソ グループ リミテッド Ｈｉｖ−ｇａｇのコドン最適化ｄｎａワクチン
DE10260805A1 (de) * 2002-12-23 2004-07-22 Geneart Gmbh Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins
DE60333035D1 (de) 2002-12-23 2010-07-29 Vical Inc Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden
US20050220816A1 (en) * 2004-03-31 2005-10-06 Advanced Bioscience Laboratories, Inc. Mutant viral nucleic acids and vaccine containing same
DE102004037611B4 (de) * 2004-08-03 2013-10-02 Geneart Ag Induzierbare Genexpression
BRPI0513081A (pt) 2004-08-03 2008-04-22 Geneart Ag método para modular a expressão gênica pela alteração do conteúdo de cpg, sistema de expressão, medicamento que o compreende e respectivos usos
ES2281252B1 (es) * 2005-07-27 2009-02-16 Consejo Superior De Investigaciones Cientificas Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2691530B1 (de) 2011-06-10 2018-03-07 Oregon Health & Science University Cmv-glycoproteine und rekombinante vektoren
EP2620446A1 (de) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogene zur HIV-Impfung
ES2599386T3 (es) 2012-04-17 2017-02-01 F. Hoffmann-La Roche Ag Método para la expresión de polipéptidos usando ácidos nucleicos modificados
CN113993888A (zh) 2019-06-28 2022-01-28 豪夫迈·罗氏有限公司 产生抗体的方法
EP4058058A1 (de) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosierungsschema für impfstoffe

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE342916T1 (de) * 1997-02-07 2006-11-15 Merck & Co Inc Synthetische hiv gag gene
WO2000015819A1 (en) * 1998-09-11 2000-03-23 The Children's Medical Center Corporation Packaging cell lines for hiv-derived retroviral vector particles
JP2003523721A (ja) * 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用

Also Published As

Publication number Publication date
DE60121572T2 (de) 2007-06-28
US20130122585A1 (en) 2013-05-16
HK1042319B (zh) 2006-10-20
EP1282712B1 (de) 2006-07-19
DE60026199D1 (de) 2006-04-27
EP1282712A2 (de) 2003-02-12
US8287881B2 (en) 2012-10-16
DE60121572D1 (de) 2006-08-31
WO2001088141A3 (en) 2002-04-18
US20070293448A1 (en) 2007-12-20
CN1429270A (zh) 2003-07-09
WO2001088141A2 (en) 2001-11-22
CA2408433A1 (en) 2001-11-22
AU2001281781A1 (en) 2001-11-26
ATE333503T1 (de) 2006-08-15
HK1042319A1 (en) 2002-08-09
EP1156112B1 (de) 2006-03-01
BR0110706A (pt) 2003-01-28
US7378515B2 (en) 2008-05-27
EP1156112A1 (de) 2001-11-21
US20040152069A1 (en) 2004-08-05
DE60026199T2 (de) 2006-11-23
HK1053853A1 (en) 2003-11-07

Similar Documents

Publication Publication Date Title
DE60026199D1 (de) Synthetische Gene für gagpol und deren Verwendungen
ATE361366T1 (de) Aus bacillus stammende transglutaminase
MXPA03000634A (es) Metodos para el reemplazo, el desplazamiento y acumulacion de adn en genomas eucarioticos.
ME00326B (me) Anti-il-12-antitjela, kompozicije, metode i njihove upotrebe
IL143326A0 (en) Method of cloning porcine animals
HRP20030088A2 (en) Anti-dual integrin antibodies, compositions, methods and uses
EP1555325A4 (de) Neue fructosylpeptidoxidase und deren nutzung
ATE257175T1 (de) Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
WO2003000038A3 (en) Compositions and methods for modulating plant development
EP0752874A4 (de) Ein verstärkter, durch viren vermittelter dna-transfer
EP1757703A3 (de) Self-inaktivierender Gammaretrovirenvektor
DK1321477T3 (da) Fremgangsmåde til frembringelsen af genetisk modificerede vertebrate precursor-lymfocytter og anvendelse deraf til fremstillingen af heterologe bindende proteiner
DE59807012D1 (de) Flip-gen und flip-protein
TR200001046T2 (tr) Homolog rekombinasyonda pozitif-negatif seçimi.
DE60233756D1 (de) Vektorvermittelte organellentransfektion
DE69940022D1 (de) Promotoren für wachstums-differenzierungsfaktoren und deren verwendung
DE50110597D1 (de) L-Aminosäure-Oxidase aus Rhodococcus-Arten
AU4903099A (en) Targeted integration into chromosomes using retroviral vectors
ZA200404424B (en) Genes encoding for genetic stability, gene expression and folding proteins.
ATE324446T1 (de) Mutante formen von etxb und ctxb und ihre verwendung als träger
AU2001240078A1 (en) Highly efficient gene transfer into human repopulating stem cells by rd114 pseudotyped retroviral vector particles
ATE329046T1 (de) Parvovirus-vektoren und deren verwendung
DE60125773D1 (de) Cds1-knockout-mäusen und davon abgeleitete zelllinien
WO2001071006A3 (de) Verfahren zur isolierung in vito differenzierter körperzellen
BRPI0401026A (pt) Processo de produção de protease e composições para limpeza

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1156112

Country of ref document: EP

EEIH Change in the person of patent owner